Mathew Lindenmayer

Mathew Lindenmayer has extensive experience in finance and accounting roles. Most recently, they served as the Vice President of Finance at Arbor Biotechnologies, starting in 2022. Prior to that, Mathew worked at Thermo Fisher Scientific from 2019 to 2022, where they held the position of Senior Director of Finance, leading the finance function for the gene therapy manufacturing business unit. Mathew also served as the Corporate Controller for the Viral Vector Services division during that time. Before joining Thermo Fisher Scientific, Mathew worked at Brammer Bio as the Controller from 2018 to 2019. In this role, they were responsible for accounting, treasury, and tax functions and successfully expanded the accounting team. Mathew began their career at PwC in 2008, initially as a Senior Associate in Assurance and later as a Director in the Capital Markets Accounting Advisory Services group. At PwC, they specialized in advising biotechnology and technology companies on initial public offerings, mergers and acquisitions, SEC financial reporting, and other capital-raising transactions. Mathew also had an internship at Permal Asset Management in 2007.

Mathew Lindenmayer holds a Master of Science in Accounting (MSA) from Babson F.W. Olin Graduate School of Business. Mathew also obtained a Bachelor of Science in Business Administration (BSBA) with a focus on Accounting from Stonehill College.